Evidence map›Paper›PMID 42321870›Full record

Trial reportBMC research notes2026

Hydroxyurea interferes with point-of-care creatinine testing in children with sickle cell anemia.

Ruth Namazzi, Robert O Opoka, Charles Ssuuna, Michael J Goings, Kathryn McElhinney, Dibyadyuti Datta, Russell E Ware, Chandy C John, Andrea L Conroy

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03528434 (for Infection Prevention in Sickle Cell Anemia), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03528434 nacompletednot on this map

for Infection Prevention in Sickle Cell Anemia (ZIPS)

TypeinterventionalSponsorIndiana UniversityRan2019 to 2020Enrolled250ConditionsSickle Cell DiseaseArmsZinc, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruth NamazziDepartment of Pediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda.
Robert O OpokaDepartment of Pediatrics and Child Health, The Aga Khan University, Nairobi, Kenya.
Charles SsuunaCHILD laboratory, Global Health Uganda, Kampala, Uganda.
Michael J GoingsRyan White Center for Pediatric Infectious Disease and Global Health, Indiana University School of Medicine, R4 402C 1044 West Walnut St, Indianapolis, IN, 46202, USA.
Kathryn McElhinneyDepartment of Pediatrics, Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Dibyadyuti DattaRyan White Center for Pediatric Infectious Disease and Global Health, Indiana University School of Medicine, R4 402C 1044 West Walnut St, Indianapolis, IN, 46202, USA.
Russell E WareDepartment of Pediatrics, Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Chandy C JohnRyan White Center for Pediatric Infectious Disease and Global Health, Indiana University School of Medicine, R4 402C 1044 West Walnut St, Indianapolis, IN, 46202, USA.
Andrea L ConroyCHILD laboratory, Global Health Uganda, Kampala, Uganda. conroya@iu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the performance of the point-of-care i-STAT device for creatinine measurement in Ugandan children with sickle cell anemia (SCA), and to determine the clinical impact of hydroxyurea-associated assay interference. RESULTS DESCRIPTION: This secondary analysis was nested within a randomized clinical trial involving 248 Ugandan children with SCA. The mean age at enrollment was 32 months, and 115/248 (46.2%) initiated hydroxyurea during 12 months of follow-up as part of routine clinical care. At enrollment, creatinine values measured by i-STAT and reference laboratory testing were clinically comparable. At follow-up, children receiving hydroxyurea had significantly higher creatinine values measured by i-STAT than by reference laboratory testing (mean difference + 0.19 mg/dL; p = 0.006), with several i-STAT results falling within the clinically abnormal range. No such discrepancy was observed among children not receiving hydroxyurea. In a subset of samples, serum hydroxyurea concentrations measured by high-performance liquid chromatography accounted for 73% of the variability in i-STAT creatinine values. These findings demonstrate clinically meaningful interference of hydroxyurea with enzymatic point-of-care creatinine testing, which may result in misclassification of kidney function and inappropriate clinical decision-making in children with SCA receiving hydroxyurea. CLINICALTRIALS: gov identifier: NCT03528434 (date registered: May 7

Indexed as

Anemia, Sickle CellAntisickling AgentsCreatinineHydroxyureaPoint-of-Care SystemsPoint-of-Care TestingChildChild, PreschoolFemaleHumansMaleUgandaAntisickling AgentsCreatinineHydroxyureaCreatinineDiagnostic accuracyHydroxyureaInterferencePoint-of-care testingSickle cell anemia

Identifiers

PMID42321870
PMCPMC13523223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.